Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.yjmcc.2020.06.007 http://scihub22266oqcxt.onion/10.1016/j.yjmcc.2020.06.007 32562701!7299869!32562701     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32562701&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Mol+Cell+Cardiol 2020 ; 145 (ä): 84-87 Nephropedia Template TP {{tp|p=32562701|t=2020. Apelin-potential therapy for COVID-19?|pdf=|usr=}}{{32562701}} gab.com Text Apelin-potential therapy for COVID-19 JO: J Mol Cell Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32562701 #FOAvip We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1-7) ratio. Twit Text FOAVip Apelin-potential therapy for COVID-19 ????J Mol Cell Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32562701 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32562701 #FOAvip English Wikipedia <ref>{{Cite pmid|32562701}}</ref> Apelin-potential therapy for COVID-19? #MMPMID32562701 Saeedi Saravi SS; Beer JH J Mol Cell Cardiol 2020[Aug]; 145 (ä): 84-87 PMID32562701show ga We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1-7) ratio. |Angiotensin I/metabolism[MESH] |Angiotensin II Type 1 Receptor Blockers/*therapeutic use[MESH] |Angiotensin II/biosynthesis/blood[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/*therapeutic use[MESH] |Animals[MESH] |Apelin Receptors/agonists/metabolism/*therapeutic use[MESH] |Apelin/metabolism/*therapeutic use[MESH] |Betacoronavirus/*metabolism[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Drug Repositioning/methods[MESH] |Humans[MESH] |Mice[MESH] |Pandemics[MESH] |Peptide Fragments/metabolism[MESH] |Peptidyl-Dipeptidase A/*metabolism[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH] |Receptor, Angiotensin, Type 1/metabolism[MESH] |Renin-Angiotensin System/drug effects/immunology[MESH]Apelin-potential therapy for COVID-19?(epmc).pdf DeepDyve Pubget Overpricing